Survodutide – Forschung

Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis.

Sun XY, Jiang HL, Ma YT, Xiong TQ, Leng XY, Zhao YF · J Transl Med (2026)

Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.

Xiao YJ, Yu S, Zhang YL, Chen J, Liu YQ, Liu XL · Diabetes Obes Metab (2025)

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.

Einfach gesagt: In total, 84.2% of survodutide-treated patients versus 24.3% of placebo-treated patients had ≥30% reduction in LFC using the efficacy estimand (P < 0.0001; treatment regimen estimand: 68.5% versus 28.6%, respectively; P < 0.0001). Mean percentage change in body weight was -12.2% with survodutide and -1.0% with placebo using the efficacy estimand.

Kaplan LM, Startseva E, le Roux CW, Wharton S, Bozkurt B, Mazo DF, von Schlippenbach J, González Maldonado S, Ajaz Hussain S, Neff GW, Gonzalez Rojas Y, Smith C, Younes R, Sanyal AJ; SYNCHRONIZE-MASLD Investigators. · Nat Med (2026)

Survodutide Once Weekly for the Treatment of Adults with Obesity.

Einfach gesagt: At week 76, the mean change in body weight from baseline according to the treatment-regimen estimand was -12.2%... in the 3.6-mg group, -13.0%... in the 6.0-mg group, and -5.4%... in the placebo group; 72.6%, 71.9% and 46.3% of the participants, respectively, had weight reduction of at least 5% (P<0.001 for all comparisons with placebo).

le Roux CW, Wharton S, Startseva E, Kloer IM, Hussain SA, Unseld A, Bozkurt B, Ard JD, Bays HE, Bogdański P, Ekinci EI, Jastreboff AM, Ji L, Ogawa W, Pedersen SD, Pietiläinen KH, Sattar N, Seufert J, Stenlöf K, van Beek AP, Vangoitsenhoven R, Brueckmann M, Younes R, Kaplan LM; SYNCHRONIZE-1 Investigators. · N Engl J Med (2026)

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.

Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E · N Engl J Med (2024)

Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity.

Ekinci EI, Maldonado SG, Unseld A, Martinez JA, Hennige AM, Schoelch C · Diabetes Obes Metab (2026)

A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity.

Yazawa R, Ishida M, Balavarca Y, Hennige AM · Diabetes Obes Metab (2023)

Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.

le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM · Lancet Diabetes Endocrinol (2024)

Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.

Blüher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM · Diabetologia (2024)

Novel GLP-1-based Medications for Type 2 Diabetes and Obesity

Einfach gesagt: We highlight how multireceptor agonists and oral GLP-1-based therapies may reshape the future landscape of obesity and type 2 diabetes treatment by offering more effective and better-tolerated options.

Son JW, le Roux CW, Blüher M, Nauck MA, Lim S. · Endocrine reviews (2026)

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial

Einfach gesagt: Conclusions The results of SYNCHRONIZE-JP will provide Japan-specific efficacy, safety and tolerability data for survodutide and inform its potential role in the management of obesity disease.

Yokote K, Yamauchi T, Fukushima Y, Takatsuka Y, Kato M, Yan S, Inoue T, Borowska L, Brueckmann M, Ogawa W, SYNCHRONIZE‐JP Trial Investigators. · Diabetes, obesity & metabolism (2026)

Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction.

Einfach gesagt: Survodutide's dual agonism of the GCGR and GLP-1 R may surpass the efficacy of selective GLP-1 R agonists, demonstrating significant potential in resolving MASH and promoting fibrosis regression.

Kaya E, Yilmaz Y, Alkhouri N. · Expert Opin Investig Drugs (2024)

Survodutide: A Dual GLP-1/Glucagon Agonist Reshaping Cardiometabolic Care.

Einfach gesagt: Phase 2 trials have demonstrated weight loss up to 18.7% and HbA1c reductions up to -1.71%, outperforming semaglutide for weight outcomes while maintaining comparable glycemic efficacy... Adverse events, primarily gastrointestinal intolerance and modest heart rate increases, remain important limitations.

Arun AJ, Darji B, Baig M, Frishman WH, Aronow WS. · Cardiol Rev (2025)

Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.

Einfach gesagt: Survodutide is generally tolerable in people with compensated or decompensated cirrhosis, does not require pharmacokinetic-related dose adjustment, and may improve liver-related non-invasive tests, supporting its investigation for MASH-related cirrhosis.

Lawitz EJ, Fraessdorf M, Neff GW, Schattenberg JM, Noureddin M, Alkhouri N, Schmid B, Andrews CP, Takács I, Hussain SA, Fenske WK, Gane EJ, Hosseini-Tabatabaei A, Sanyal AJ, Mazo DF, Younes R. · J Hepatol (2024)